Cue Biopharma, a Boston-based clinical-stage biopharmaceutical company, develops biologic drugs for immune system modulation to treat cancers and autoimmune disorders. Its key candidates include CUE-101 for HPV-positive HNSCC and CUE-102 for Wilms' Tumor 1 protein.
Cue Biopharma (CUE) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cue Biopharma's actual EPS was -$0.17, missing the estimate of -$0.15 per share, resulting in a -9.75% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
